Knock out Mouse Model Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Knockout Mouse Model Market Is Segmented By type(Conditional Knockout, Constitutive Knockout Mouse, Protein Function Knockout Mouse), By End-User (Clinical Research Organizations, Pharma & Biotechnology Companies, others),  and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Knockout Mouse Model Market Overview

The global "knockout mouse model market" size is estimated to reach at a high CAGR during the forecast period 2023-2030

A knockout mouse is an animal model in which one or more important genes are disrupted or inactivated through gene targeting. Gene activity loss frequently causes phenotypic changes in the model animal, allowing in vivo studies of gene function and biological mechanisms.

Knockout Mouse Model Market Scope

To Know More: Download Sample

Knockout Mouse Model Dynamics

Factors driving the knockout mouse model growth include the increasing development of drugs.

Increasing development of drugs is expected to drive the knockout mouse model market

A knockout mouse is a laboratory mouse that has had one or more genes turned off or knocked out. Knockout mice are used to investigate what happens in an organism when a specific gene is missing. The study of knockout mice can provide information about how the knocked-out gene normally functions, including the gene's biochemical, developmental, physical, and behavioral roles. Because humans and mice share many genes,  mice are frequently used to study human diseases and discover the functions of human genes. Drug development and preclinical trials are now, more than ever, time-consuming and costly processes. These processes have a high attrition rate, and only about 10% of the compounds tested in clinical trials are approved by the US Food and Drug Administration. The use of low-cost, experimentally manageable in vivo animal models is one solution to the significant challenges of developing new drugs and combination therapies. Genetically engineered mouse models of human disease (GEMMs) could aid in drug development. GEMMs of various types, including transgenic, knockout, and knock-in mouse models, have been used in drug development and preclinical trials.

Drawbacks of knock out mouse model are expected to hamper the market growth

While knockout mice technology is a valuable research tool, it does have some significant limitations. Around 15% of gene knockouts are developmentally lethal, meaning genetically altered embryos cannot develop into adult mice. The lack of adult mice limits studies to embryonic development and often makes determining a gene's function with human health more difficult. In some cases, the gene may serve a different purpose in adults than in developing embryos.

Knocking out a gene may fail to produce an observable change in a mouse or produce characteristics that differ from those seen when the same gene is inactivated in humans. For example, mutations in the p53 gene have been linked to more than half of all human cancers and frequently result in tumors in a specific set of issues. When mice have their p53 gene knocked out, they develop tumors in a variety of tissues.

COVID-19 Impact Analysis On Knockout Mouse Model Market

Genetically engineered mouse models (GEMs) have been useful in developing new SARS treatments and vaccines, and they are also expected to be useful in the research of COVID-19 treatments. The use of GEM knockout (KO) mouse models of angiotensin-converting enzyme (Ace2) and transmembrane protease serine-type 2 (Tmprss2) in demonstrating the critical roles that these proteins play in SARS infection and the development of pulmonary symptoms. Within human cells, the SARS S protein binds to the ACE2 receptor, which TMPRSS2 further primes. Ace2 knockout mice have been crucial in SARS and ARDS research, demonstrating that binding of SARS viral S protein to ACE2 in mice down-regulates ACE2 expression and that ACE2 expression loss is associated with severe lung failure. Similarly, Tmprss2 knockout mice have been used in SARS research to show that Tmprss2 is involved in SARS-CoV entry into cells and that inhibiting it may be a treatment/prevention mechanism. Emerging literature supports the use of these Ace2 and Tmprss2 GEM models for concurrent research into COVID-19 disease pathogenesis and treatment. Hence, due to COVID-19, there was a demand for theglobal knock-out mouse model market.

Knockout Mouse Model Market Segment Analysis

The Conditional Knockout Mouse segment is expected to dominate the global knock out mouse model market

A conditional knockout model is one in which a gene of interest is deleted only from one tissue or organ. This model entails the deletion of a gene at a specific time or in a specific tissue. The conditional knockout model is more advanced than a constitutive knockout model. It only deletes a gene in the targeted organ or tissue. For example, a conditional knockout model is used to study a liver disease (organ). In this case, scientists remove that specific gene from the liver. The side effects of conventional knockout are eliminated by conditional knockout.

Conditional knockout allows for the deletion of genes at a specific developmental stage. It also enables us to investigate how a gene knockout in one tissue affects the same gene in other tissues. This model is frequently used to investigate human diseases in other mammals. Using CRISPR gene-editing technology, a conditional knockout mouse model can be created in 6 to 9 months. The gene of interest is inactivated in a specific tissue type or at a specific time point in a conditional knockout. The gene of interest is permanently inactivated in the constitutive knockout. This is the primary distinction between conditional and constitutive knockout. Conditional knockout is a more targeted form of a knockout than constitutive knockout. Furthermore, a conditional knockout is safer and more effective than a constitutive knockout.

Knockout Mouse Model Market Geographical Analysis

North America region accounted for the largest market share in theglobal knock out mouse model market

Many large biotechnological and biopharmaceutical firms are present in developed countries such as the United States and Canada. Scientific discoveries, new technologies, and creative applications of cutting-edge knowledge are becoming increasingly important for success in a competitive global economy and addressing challenges and opportunities in diverse societal areas such as health, the environment, and national security. The overall R&D enterprise in the United States is dependent on the R&D performance and funding, which includes businesses, the federal government, non-federal governments, higher education institutions, and other non-profit organizations.

The National Institutes of Health-funded three "KOMP2" centers in the United States, one of which is located at The Jackson Laboratory, to collaborate on the massive task of producing and phenotyping knockout mice.

Knockout Mouse Model Market Competitive Landscape

The global knock-out mouse model market is highly competitive with research, product development, manufacturing, distribution, and sales players. Some of the major key players in the global knock-out mouse model market are The Jackson Laboratory, Charles River Laboratories, Inc., Taconic Biosciences, Inc., Harlon Laboratories, GenOway, ingenious targeting laboratory, Applied StemCell, Creative Biogene, TransGenic Inc., and Envigo.

Envigo

Overview: Envigo, an Inotiv company, offers a comprehensive set of research models and related services to the biotechnology and pharmaceutical industries, as well as government, academia, and other life science organizations. Envigo employs over 1,200 people in over 20 locations across North America and Europe.

Product Portfolio: The company has B-NDG knockout mice and Rag2-Il2rg double knockout mice (R2G2).

Key Development: On 3rd April 2017, Envigo launched the R2G2 double knockout mouse model. The R2G2, a Rag2/IL2RG double knockout model, was created by backcrossing the common gamma chain gene mutation (IL2RG) onto a unique C57BL/6 and 129 mixed background mice with a mutation in the recombination activating gene two resulted in the R2G2, a Rag2/IL2RG double knockout model (Rag2). Envigo’sR2G2 mouse addresses common issues that researchers face when using current oncology, immuno-oncology, and infectious disease research models.